Wikipedia

Laboratoires Pierre Fabre

(Redirected from Pierre Fabre Group)

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company. The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).[2] It is headquartered in the city of Castres, Midi-Pyrénées, France.[2]

Pierre Fabre S.A.
Company typePrivate limited company
IndustryPharmaceutical
Founded1962 (1962)
HeadquartersParis, France[1]
Area served
Worldwide
Key people
  • Eric Ducournau
  • (President and CEO)
Number of employees
13,000 (2015) (Homepage)
Websitewww.pierre-fabre.com

Founded in 1962 by Pierre Fabre (1926-2013),[2] the company is present in over 130 countries. Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France.[2] The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. Pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover).[citation needed]

Pierre Fabre is best known for its vinorelbine (Navelbine),[3][4] an anticancer drug[5] of the vinca alkaloid class.[6][7][8] They also developed vinflunine,[9] a fluorinated vinca alkaloid derivative[10][11] available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen."[12]

Olivier Bohuon was Chief Executive from September 2010 to April 2011.[13]

The Pierre Fabre Foundation

edit

The Pierre Fabre Foundation was recognized as a public utility in 1999,[14] and its mission is to enable communities from less advanced and emerging countries, as well as those plunged into severe crisis by political or economic upheaval and/or natural disaster, to access the quality and levels of everyday health care and the widely-used drugs defined by the WHO and other organisations as essential to human health.[15]

References

edit
  1. ^ "Company Overview of Pierre Fabre S.A." Archived from the original on January 1, 2009. Retrieved December 9, 2014.
  2. ^ a b c d "Pierre Fabre, founder of pharmaceutical giant, dies". Agence France Presse. France 24. 2013-07-20. Archived from the original on 2013-07-23. Retrieved 2013-08-17.
  3. ^ Ngo, Quoc Anh; Roussi, Fanny; Cormier, Anthony; Thoret, Sylviane; Knossow, Marcel; Guénard, Daniel; Guéritte, Françoise (2009). "Synthesis and biological evaluation of Vinca alkaloids and phomopsin hybrids". Journal of Medicinal Chemistry. 52 (1): 134–142. doi:10.1021/jm801064y. PMID 19072542.
  4. ^ Keglevich, Péter; Hazai, Laszlo; Kalaus, György; Szántay, Csaba (2012). "Modifications on the basic skeletons of vinblastine and vincristine". Molecules. 17 (5): 5893–5914. doi:10.3390/molecules17055893. PMC 6268133. PMID 22609781.
  5. ^ Faller, Bryan A.; Pandi, Trailokya N. (2011). "Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer". Clinical Medicine Insights: Oncology. 5: 131–144. doi:10.4137/CMO.S5074. PMC 3117629. PMID 21695100.
  6. ^ van der Heijden, Robert; Jacobs, Denise I.; Snoeijer, Wim; Hallard, Didier; Verpoorte, Robert (2004). "The Catharanthus alkaloids: Pharmacognosy and biotechnology". Current Medicinal Chemistry. 11 (5): 607–628. doi:10.2174/0929867043455846. PMID 15032608.
  7. ^ Raviña, Enrique (2011). "Vinca alkaloids". The evolution of drug discovery: From traditional medicines to modern drugs. John Wiley & Sons. pp. 157–159. ISBN 9783527326693.
  8. ^ Cooper, Raymond; Deakin, Jeffrey John (2016). "Africa's gift to the world". Botanical Miracles: Chemistry of Plants That Changed the World. CRC Press. pp. 46–51. ISBN 9781498704304.
  9. ^ "Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status" (Press release). Bristol-Myers Squibb. November 23, 2007. Archived from the original on May 28, 2008. Retrieved June 27, 2008.
  10. ^ Fahy, Jacques; Duflos, Alain; Ribet, Jean-Paul; Jacquesy, Jean-Claude; Berrier, Christian; Jouannetaud, Marie-Paule; Zunino, Fabien (1997). "Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives". J. Am. Chem. Soc. 119 (36): 8576–8577. doi:10.1021/ja971864w.
  11. ^ Kruczynski, Anna; Barret, Jean-Marc; Etiévant, Chantal; Colpaert, Francis; Fahy, Jacques; Hill, Bridget T. (1998). "Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid". Biochem. Pharmacol. 55 (5): 635–648. doi:10.1016/S0006-2952(97)00505-4. PMID 9515574.
  12. ^ "Vinflunine, solution concentration for I.V. infusion, 50 mg in 2 mL and 250 mg in 10 mL (as ditartrate), Javlor® – November 2011". Pharmaceutical Benefits Scheme. March 16, 2012. Retrieved June 22, 2017.
  13. ^ "Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA". FierceBiotech. Retrieved 2020-01-29.
  14. ^ pbouchayer. "History". Fondation Pierre Fabre. Retrieved 2021-09-19.
  15. ^ pbouchayer. "DNA". Fondation Pierre Fabre. Retrieved 2021-09-19.
edit


 

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Laboratoires_Pierre_Fabre&oldid=1245419120"